Therapies for Rheumatoid Arthritis: Technologies and Global Markets

Description: The global market for therapies for rheumatoid arthritis reached $19.0 billion in 2014. The market is expected to reach nearly $21.3 billion by 2020 from $19.9 billion in 2015, increasing at a compound annual growth rate (CAGR) of 1.3% from 2015 to 2020.

This report provides:

- An overview of the global markets, therapies, and related technologies for treating Rheumatoid Arthritis (RA).
- Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Discussion covering suppliers of therapeutic products for RA and analysis based on market share, product types, and geography (where data is available).
- An overview of the disease including etiology, epidemiology, pathophysiology, risk factors and co-morbidities, and progression and outcomes.
- An in-depth pipeline analysis, and biologic agents, both anti-TNF and non-TNF related currently under investigation or newly approved for use by the FDA are highlighted.
- Relevant patent analysis.
- Profiles of major players in the industry.

Contents:

1: Introduction
- Study Goals And Objectives
- Reasons For Doing This Study
- Intended Audience
- Scope Of Report
- Methodology
- Information Sources

2: Summary
- Table 0A: Global Market For Therapies For Rheumatoid Arthritis, By Therapeutic Class, Through 2020
- Figure 0A: Global Market For Therapies For Rheumatoid Arthritis By Therapeutic Class, 2014-2020
- Table 0B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, Through 2020
- Figure 0B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, 2014-2020

3: Disease Overview
- Etiology
- Pathophysiology
- Symptoms
- Prognosis
- Quality Of Life
- Epidemiology

4: Disease Management
- Diagnosis
- Treatment Overview
- Biosimilars
- Competitive Assessment

5: Unmet Need And Opportunity
6: Pipeline Assessment
- Overview

7: Patent Assessments
- Table 33: List of Therapies for RA in the Market, By Patent Expiry Date
- Table 34: List of Patents Issued for RA Therapies
- Table 35: List of Patent Applications for RA Therapies

8: Company Profiles
- Ab Science
- Abbott Laboratories
- Amgen Inc.
- Astellas
- Baxalta Inc.
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Celgene Corp.
- Celltrion Inc.
- Coherus Biosciences Inc.
- Daiichi Sankyo Co. Ltd.
- Eisai
- Eli Lilly
- Fujifilm Kyowa Kirin Biologics Co. Ltd.
- GlaxoSmithkline
- Incyte Corp.
- Johnson & Johnson
- Kineta Inc.
- Mabtech AB
- Mycenax Biotech Inc.
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Pfizer
- Roche
- Samsung Biologics Co. Ltd.
- Takeda Pharmaceuticals
- UCB Group/Immunomedics

9: Drivers And Barriers
- Driver: Launch Of Novel Drugs, Including Oral Jak Inhibitors And Novel Biologics For RA
- Driver: Earlier Diagnosis And Treatment
- Driver: Market Entry Of Biosimilars Will Bring A Therapy Option For Those Who Cannot Afford Branded Biologics
- Driver: Aging Population And Increasing Prevalent Cases Of RA
- Barrier: Efforts To Reduce Costs In The Treatment Of RA
- Barrier: Lack Of Regulatory Guidelines For Biosimilars Will Delay Their Availability In Some Regions
- Barrier: Entry Of Biosimilars Will Create A Less Expensive Treatment Alternative
- Table 36: Drivers And Barriers For RA Therapies

List Of Tables
- Summary Table A: Global Market For Therapies For Rheumatoid Arthritis, By Therapeutic Class, Through 2020
- Summary Table B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, Through 2020
- Table 1: Common Symptoms Of Rheumatoid Arthritis
- Table 2: Epidemiological Forecast For Diagnosed Prevalent Cases Of Rheumatoid Arthritis, By Region, Through 2020
- Table 3: Risk Factors And Comorbidities For Rheumatoid Arthritis
- Table 4: The 1987 ACR Diagnostic Criteria For RA
Table 5: The 2010 Acr/Eular Diagnostic Criteria For Ra
Table 6: Treatment Guidelines For Ra
Table 7: The Acr 2012 Criteria For Ra Remission, And Low, Moderate, And High Disease Activity
Table 8: The Acr/Eular 2011 Criteria For Ra Remission Used In The 2013 Update To The Eular Recommendations For Ra Management
Table 9: Recommendations For Patients With Symptomatic Early Ra
Table 10: Recommendations For Optimal Followup Laboratory Monitoring Intervals*
Table 11: Mostmost Prescribed Biologics For The Treatment Of Ra (After Csdmards), By Region
Table 12: Minor Therapeutic Drug Classes Used To Treat Ra
Table 13: Ra Diagnosis Profile In The U.S.
Table 14: Ra Diagnosis Profile In France
Table 15: Ra Diagnosis Profile In Germany
Table 16: Ra Diagnosis Profile In Italy
Table 17: Ra Diagnosis Profile In Spain
Table 18: Ra Diagnosis Profile In The Uk
Table 19: Ra Diagnosis Profile In Japan
Table 20: Ra Diagnosis Profile In Australia
Table 21: Ra Diagnosis Profile In China
Table 22: Ra Diagnosis Profile In India
Table 23: Leading Drugs For Treatment Of Ra
Table 24: Global Market For Major Biosimilars By Region And Type, Through 2020
Table 25: Global Market For Enbrel, By Region, Through 2020
Table 26: Global Market For Humira, By Region, Through 2020
Table 27: Global Market For Remicade (Infliximab), By Region, Through 2020
Table 28: Global Market For Actemra, By Region, Through 2020
Table 29: Global Market For Orencia (Abatacept), By Region, Through 2020
Table 30: Global Market For Rituxan (Mabthera), By Region, Through 2020
Table 31: List Of Ra Therapies In Clinical Trials, By Phase
Table 32: List Of Ra Therapies In Development, By Phase
Table 33: List Of Therapies For Ra In The Market, By Patent Expiry Date
Table 34: List Of Patents Issued For Ra Therapies
Table 35: List Of Patent Applications For Ra Therapies
Table 36: Drivers And Barriers For Ra Therapies

List Of Figures

Summary Figure A: Global Market For Therapies For Rheumatoid Arthritis By Therapeutic Class, 2014-2020
Summary Figure B: Global Market For Therapeutic Products For Rheumatoid Arthritis By Region, 2014-2020
Figure 1: Flowchart For The Management Of Ra In Early Disease, According To The Acr2012 Recommendations
Figure 2: Flowchart For The Management Of Ra In Established Disease, According To The Acr2012 Recommendations
Figure 3: Recommendations For Treatment Of Early Ra
Figure 4: Flowchart For The Management Of Patients With Ra, According To The 2013 Eular Recommendations

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3789258/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Therapies for Rheumatoid Arthritis: Technologies and Global Markets
Web Address: http://www.researchandmarkets.com/reports/3789258/
Office Code: SCBR91PJ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 6650</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>□</td>
<td>USD 8500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Select] Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World